<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Crown Bioscience Adds Former Distinguished Eli Lilly Scholar to its Senior Management Team

SANTA CLARA, Calif.–(EON: Enhanced Online News)–Crown Bioscience, Inc.,
a preclinical oncology CRO, announced today that Dr. Chuan (Joe) Shih has
accepted the position of Executive Vice President, Integrated Drug Discovery
Services Business Unit.

“DR. SHIH IS WIDELY REGARDED AS ONE OF THE INDUSTRY’S LEADING EXPERTS IN
ONCOLOGY DRUG DISCOVERY AND DEVELOPMENT. HE WILL BRING A UNIQUE
PERSPECTIVE TO THE COMPANY AS WE CONTINUE TO IDENTIFY NEW OPPORTUNITIES
THAT HELP OUR CLIENTS ACCELERATE THEIR DRUG DISCOVERY AND DEVELOPMENT
PROGRAMS”

Prior to joining Crown, Dr. Joe Shih, Ph.D., was a Distinguished Lilly Scholar of

Discovery Chemistry Research and Technology at Lilly Research Laboratories
(LRL), a Division of Eli Lilly and Company. Joe received a doctorate in Organic
Chemistry from The Ohio State University in 1982. He was also awarded a
Bachelor of Science in Chemistry from the National Chung-Hsing University,
Taiwan in 1976, and a Master of Science in Organic Chemistry from The Ohio
State University in 1979. Dr. Shih completed a postdoctoral fellowship at Harvard
University under Nobel Laureate Professor E. J. Corey from 1982 to 1984.

Following his postdoctoral studies, he joined Lilly as a Senior Organic Chemist in
1984. He was promoted to Research Scientist in 1989, to Senior Research Scientist
in 1993, to Research Advisor in 1999, to Distinguished Research Fellow in 2004
and to Distinguished Lilly Scholarin 2007.

During his tenure at Eli Lilly, Dr. Shih has distinguished himself as a premier
drug hunter by contributing to many LRL oncology drug discovery efforts.
Through his collaboration with Princeton University, Dr. Shih contributed to the
successful antifolate drug discovery program that has led to the development of
ALIMTA®, a blockbuster anticancer agent approved by various regulatory
agencies around the globe for the treatment of mesothelioma and non-small cell
lung cancer. Dr Shih is a co-inventor of ALIMTA® and a pioneerin the elucidation
of the unique “multi-targeted antifolate” mechanism of action of ALIMTA®. Dr.
Shih was awarded the 2006 American Chemical Society “Heroes of Chemistry”. Award for his role in the discovery and development of ALIMTA®.

Dr. Shih was also instrumental in leading various medicinal chemistry and drug discovery initiatives and efforts in the identification of several novel anticancer

agents currently in the Lilly Oncology pipeline. Dr. Shih is widely recognized for
his expertise in cancer and medicinal chemistry research. He is frequently invited
to lecture and chair sessions at national and international meetings. Dr. Shih has
authored and co-authored more than 180 scientific publications and presentations
and holds numerous patents. Dr. Shih is also holding a position of visiting
Distinguished Chair Professor of Pharmaceutical Sciences at the Department of
Applied Biology and Chemical Technology of The Hong Kong Polytechnic
University.

“Dr. Shih is widely regarded as one of the industry’s leading experts in oncology
drug discovery and development. He will bring a unique perspective to the
company as we continue to identify new opportunities that help our clients
accelerate their drug discovery and development programs,” said Alex Wu, Chief
Executive Officer of CrownBio.

“CrownBio’s reputation for scientific and service excellence, consistent quality
and commitment to supporting the discovery of anti-tumor therapeutics is
unparalleled in the industry,” said Dr. Shih. “I look forward to working with this
truly talented team as well as playing a role in the Company’s growth.”
About Crown Bioscience,Inc.

Crown Bioscience, Inc. is a U.S.-based drug discovery service company with R&D
facilities in China committed to advancing anti-cancer therapeutics through the
preclinical and drug development stages. Its proprietary CrystalClear™,
HuPrime™ and HuKemia™ platforms enable unique lead optimization and
translational oncology strategies to deliver better clinical candidates. Our team of
experts provides an integrated service solution from idea to IND, including:
preclinical, translational, and clinical capabilities.

Upcoming Events

Happy Hour Social: Mixing Science, Sips, and Connections

August 13, 2024|Farmer and Seahorse in La Jolla | San Diego, CA

Learn More

Happy Hour Social: Mixing Science, Sips, and Connections

August 15, 2024|Chandlery at the Shore | Brisbane, CA

Learn More

CRI-ENCI Eighth International Cancer Immunotherapy Conference: Translating Science into Survival

September 8-11, 2024|Gaylord National Resort & Convention Center | Washington, DC

Learn More

Biomarkers Europe 2024

September 30 - October 1, 2024|Basel, Switzerland

Learn More